Tysabri (natalizumab)
Lemtrada (alemtuzumab)
Effective 01/01/2022

<table>
<thead>
<tr>
<th>Plan</th>
<th>☐ MassHealth</th>
<th>☒ Commercial/Exchange</th>
<th>Program Type</th>
<th>☒ Prior Authorization</th>
<th>☒ Quantity Limit</th>
<th>☐ Step Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benefit</td>
<td>☒ Pharmacy Benefit</td>
<td>☒ Medical Benefit (NLX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Specialty Limitations: N/A

Contact Information:

**Specialty Medications**

| All Plans | Phone: 866-814-5506 | Fax: 866-249-6155 |

**Non-Specialty Medications**

| MassHealth | Phone: 877-433-7643 | Fax: 866-255-7569 |
| Commercial | Phone: 800-294-5979 | Fax: 888-836-0730 |
| Exchange   | Phone: 855-582-2022 | Fax: 855-245-2134 |

**Medical Specialty Medications (NLX)**

| All Plans | Phone: 844-345-2803 | Fax: 844-851-0882 |

Exceptions: N/A

Overview

Tysabri and Lemtrada are monoclonal antibody disease-modifying drugs. Tysabri is indicated for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome (CIS), relapsing-remitting (RRMS) and active secondary progressive (SPMS) in adults. Tysabri is also indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. Lemtrada is indicated for RRMS and SPMS in adults.

Coverage Guidelines

Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Tysabri or Lemtrada excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**

Authorization may be granted for members for Tysabri or Lemtrada when the following criteria are met, and documentation is provided:

**Multiple Sclerosis - Tysabri and Lemtrada**

1. The member is diagnosed with a relapsing form of MS, including RRMS, CIS or active SPMS
2. The member is ≥ 18 years of age
3. **For Lemtrada,** the member has an inadequate response, adverse reaction or contraindication to Tysabri AND Ocrevus.
Crohn’s Disease – Tysabri ONLY
1. The member is diagnosed with a moderate to severely active Crohn’s disease
2. The member is ≥ 18 years of age
3. The member has had previous use of any biologic agent
4. The member is NOT using Tysabri with an immunosuppressants (e.g., 6-mercaptopurine, azathioprine, cyclosporine, or methotrexate) or inhibitors of TNF-α.

Continuation of Therapy
Reauthorization requires physician documentation of improvement of member’s condition.

Limitations
1. All indications for Tysabri, approvals for will be authorized for 12 months
2. For Lemtrada, approval of 2 treatment courses in 24 months will be authorized. The first course is administered as 12mg/day on 5 consecutive days. The second course, given 12 months after the first course, is administered as 12mg/day on 3 consecutive days. Requests for subsequent treatments of 12mg/day for 3 consecutive days at least 12 months after the last treatment course, will require submission of medical necessity by the prescriber.

References

Review History
11/18/2020- Updated- combined Tysabri and Lemtrada into one document, changed Tysabri to preferred product, Reviewed by P+T
11/17/2021 – Updated and reviewed Nov P&T; updated benefit type to pharmacy and medical. Effective 1/1/2022

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.